

**Publication of materials for holding a Regular General Meeting of Shareholders of “Sopharma” AD,
scheduled for 2 June 2023**

Sofia, Bulgaria, 28 April 2023 - According to the requirements of Art. 100t of the Law on Public Offering of Securities the Board of directors of “**Sopharma**” AD (SFA: “BSE – Sofia”, SPH: Warsaw Stock Exchange) presents the following materials on the agenda of AGM convened for 2 June 2023 to the attention of shareholders, which will be available on the website of Extri News (www.x3news.com), in the FSC system, on the Company's website <https://www.sopharmagroup.com/bg/investitori/obshcho-sbranie-na-akcionerite> and on the website www.investor.bg, as well as in hard copy at the address of the Company:

1. Minutes of a meeting of the Board of Directors for convening an Annual Meeting of Shareholders of “Sopharma” AD;
2. Invitation to convene the Annual Meeting of Shareholders (AGM) of “Sopharma” AD;
3. Power of attorney – an example for representing a shareholder at the AGM;
4. Declaration for voting by correspondence – an example for the AGM;
5. **For items 1 and 9 of the agenda:** Annual Report of the Board of Directors for the company's activities in 2022 – already available on the website of Extri News (www.x3news.bg), in the FSC system, on the company's website <http://www.sopharmagroup.com/bg/investitori/finansovi-otcheti> and on the website www.investor.bg;
6. **For item 2 of the agenda:** Report of the Investor Relations Director for 2022;
7. **For items 3, 7 and 12 of the agenda:** Audited Annual Individual financial statements of the Company in 2022 - already available on the website of Extri News (www.x3news.bg), in the FSC system, on the company's website <http://www.sopharmagroup.com/bg/investitori/finansovi-otcheti> and on the website www.investor.bg;
8. **For item 4 of the agenda:** Audited Annual Consolidated financial statements of the Company for 2022 - already available on the website of Extri News (www.x3news.bg), in the FSC system, on the company's website <http://www.sopharmagroup.com/bg/investitori/finansovi-otcheti> and on the website www.investor.bg;
9. **For item 5 of the agenda:** Auditor's Report on the Audit of the Annual Individual financial statements of the Company in 2022 - already available on the website of Extri News (www.x3news.bg), in the FSC system, on the company's website <http://www.sopharmagroup.com/bg/investitori/finansovi-otcheti> and on the website www.investor.bg;

10. **For item 6 of the agenda:** Auditor's Report on the Audit of the Annual Consolidated financial statements of the Company for 2022 - already available on the website of Extri News (www.x3news.bg), in the FSC system, on the company's website <http://www.sopharmagroup.com/bg/investitori/finansovi-otcheti> and on the website www.investor.bg;
11. **For items 8 and 11 of the agenda:** Report of the Audit Committee's activities in 2022;
12. **For item 10 of the agenda:** Proposal by the Chairman of the Board of Directors of "Sopharma" AD for the election of members of the Audit Committee due to the expiration of its mandate, information on the qualifications of the proposed members and declarations;
13. **For items from 16 and 17 of the agenda:** Substantiated Report of the Board of directors on transactions within the scope of Art. 114 of LPOS and market valuation to it.



Pelagia Viatcheva

Investor Relations Director



Information about the company

Sopharma AD

Nearly 90 years of tradition and modernity - contemporary production, European standards and quality, best practices in the field of corporate and social responsibility.

Sopharma AD is the most successful Bulgarian company after the privatization, as from 2000 to today, the company realized 10 times growth in market capitalization and 25 times revenue growth. Over the past 10 years, Sopharma AD has been a leader in the pharmaceutical sector in Bulgaria.

Sopharma AD produces active substances and medicinal products; conducts activities related to development and implementation in the field of phytochemistry, chemistry and pharmacy, provides services related to production and other.

With 9 pharmaceutical plants in the country and the only ampoule factory in Bulgaria the company produces 3 billion tablets, 20 million syrup forms, has an authorization for over 200 generic products, 15 traditional products, 12 of which are plant-based, and uses more than 1500 tons of medicinal plants in its products.

Sopharma AD has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma AD is constantly investing in new technologies, innovations and research. The company maintains a dialogue with all players in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group



Sopharma Group is a vertically integrated healthcare business that operates in important health related sectors such as pharmaceuticals, hospital supplies, pharmaceutical products distribution and many others. "Sopharma" AD and its production subsidiaries have 8 pharmaceutical plants in Bulgaria, complying with the requirements of EU– GMP.